SANA AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.926 SEK | -1.13% |
|
-9.15% | -51.97% |
| 08/05 | Terna in first quarter increases profit and revenues by double digits | AN |
| 30/04 | Imprendiroma, indicators increase to triple digits in 2023 | AN |
Presenter SpeechTrista Morrison (Executives)Thank you, and welcome, everyone, to today's webca...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Saniona AB is a Sweden-based company active in the field of biotechnology. It operates in the area of drugs targeting ion channels to develop therapeutics for pain, central nervous system, and inflammatory or autoimmune diseases. The Company develops a technology platform which enables investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors and potassium channels. The clinical pipeline includes: AN788, a clinical candidate for second line treatment of major depressive disorder (MDD); AN761, to be developed for cognition deficits in schizophrenia and Alzheimer's disease; AN363, a candidate for treatment of pain disorders; and AN346, an anti-inflammatory treatment in inflammatory bowel disease (IBD); as well as several other projects. The Company is engaged in partnerships with Janssen Pharmaceuticals Inc, Pfizer Inc and Atlas Venture Inc.
Calendar
21/08/2024
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -51.97% | 20.18M | |
| +10.79% | 116B | |
| +11.65% | 106B | |
| -6.20% | 23.89B | |
| -3.52% | 21.58B | |
| -11.25% | 18.96B | |
| -40.50% | 16.96B | |
| -13.41% | 16.33B | |
| +6.64% | 14.14B | |
| +31.84% | 12.02B |
- Stock Market
- Equities
- SANION Stock
- News SANA AB
- Transcript : Saniona AB - Special Call
